Combo Therapy Boosts Survival in Resectable Biliary Tract Cancer

By News Health
3 weeks Ago

(MedPage Today) — Camrelizumab, an investigational immunotherapy, on top of adjuvant capecitabine (Xeloda) and radiotherapy, improved survival outcomes in patients with resectable biliary tract cancers (extrahepatic cholangiocarcinoma [EHC] and…

Source link : https://www.medpagetoday.com/hematologyoncology/othercancers/116452

Author :

Publish date : 2025-07-10 17:25:00

Copyright for syndicated content belongs to the linked Source.

Categories: Health News

Related Content

Atropine Drops for Vitreous Floaters Show Promise as Less Invasive Alternative

'I Can't Pee Like I Used to Pee': What We Heard This Week

Subcutaneous Lecanemab Maintenance Dosing for Alzheimer's Supported by New Data

Advice to Young Physicians: Avoid the Headhunters

Artists help Tamworth pupils and cancer centre users create murals

Combination Therapy for AMD Fails to Improve Vision Versus Single Drug